Shares of Cambrex Co. (NYSE:CBM) have received an average rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $61.17.
A number of analysts recently commented on CBM shares. Zacks Investment Research cut shares of Cambrex from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. ValuEngine lowered shares of Cambrex from a “sell” rating to a “strong sell” rating in a report on Thursday, January 31st. Craig Hallum reduced their target price on shares of Cambrex from $71.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, February 14th. Robert W. Baird assumed coverage on shares of Cambrex in a report on Thursday, November 15th. They set an “outperform” rating on the stock. Finally, First Analysis raised shares of Cambrex from an “outperform” rating to a “strong-buy” rating and dropped their price target for the company from $73.00 to $63.00 in a research report on Friday, November 9th.
Shares of CBM stock opened at $40.19 on Friday. The company has a market cap of $1.29 billion, a P/E ratio of 14.51, a price-to-earnings-growth ratio of 1.29 and a beta of 2.45. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.86 and a current ratio of 3.93. Cambrex has a 12 month low of $33.80 and a 12 month high of $69.43.
In other Cambrex news, COO Shawn Cavanagh sold 6,769 shares of the stock in a transaction on Friday, February 15th. The shares were sold at an average price of $37.60, for a total transaction of $254,514.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Gregory Sargen sold 5,802 shares of the stock in a transaction on Friday, February 15th. The shares were sold at an average price of $37.45, for a total transaction of $217,284.90. The disclosure for this sale can be found here. Corporate insiders own 2.42% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Teachers Advisors LLC increased its stake in Cambrex by 19.8% during the 3rd quarter. Teachers Advisors LLC now owns 73,543 shares of the biotechnology company’s stock valued at $5,030,000 after purchasing an additional 12,166 shares in the last quarter. Northpointe Capital LLC bought a new stake in Cambrex during the 3rd quarter valued at about $2,404,000. Jane Street Group LLC bought a new stake in Cambrex during the 3rd quarter valued at about $321,000. MetLife Investment Advisors LLC increased its stake in Cambrex by 56.3% during the 3rd quarter. MetLife Investment Advisors LLC now owns 23,719 shares of the biotechnology company’s stock valued at $1,622,000 after purchasing an additional 8,539 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Cambrex by 54.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 210,069 shares of the biotechnology company’s stock valued at $14,358,000 after purchasing an additional 74,162 shares in the last quarter.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Recommended Story: Cost of equity and a company’s balance sheet
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.